Can new pills tame high blood pressure?

NCT ID NCT06291207

Completed Disease control Sponsor: Addpharma Inc. Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This clinical trial is testing whether two experimental oral medications, AD-224A and AD-224B, can safely lower blood pressure in people with essential hypertension (high blood pressure with no known cause). About 254 participants will take one of the drugs or a placebo once daily for 8 weeks. The main goal is to see how much the drugs reduce sitting systolic blood pressure compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AD-224A and AD-224B (oral drugs taken once daily for 8 weeks)
What this could lead to: If successful, these oral medications could offer a new option for controlling high blood pressure, potentially reducing the risk of heart attack and stroke.
What could go wrong: This is a phase 3 trial, but results are not yet known. The drugs may not lower blood pressure enough or could cause side effects. Success in this trial does not guarantee approval or widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION,ESSENTIAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension essential hypertension, genetic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION,ESSENTIAL

Contacts and locations

Locations

Seoul National University Bundang Hospital

Seongnam-si, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.